192 related articles for article (PubMed ID: 2437338)
21. Platelet factor 4 (PF4) and heparin-released platelet factor 4 (HR-PF4) in patients with cardiovascular disorders.
Cella G; Colby SI; Taylor AD; McCracken L; Parisi AF; Sasahara AA
Thromb Res; 1983 Mar; 29(5):499-509. PubMed ID: 6222505
[TBL] [Abstract][Full Text] [Related]
22. Platelet activation during steady state sickle cell disease.
Westwick J; Watson-Williams EJ; Krishnamurthi S; Marks G; Ellis V; Scully MF; White JM; Kakkar VV
J Med; 1983; 14(1):17-36. PubMed ID: 6224876
[TBL] [Abstract][Full Text] [Related]
23. The novel effect of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood.
Saniabadi AR; Lowe GD; Belch JJ; Forbes CD; Prentice CR; Barbenel JC
Thromb Haemost; 1983 Oct; 50(3):718-21. PubMed ID: 6196854
[TBL] [Abstract][Full Text] [Related]
24. Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism.
Sobel M; Adelman B; Szentpetery S; Hoffman M; Posner MP; Jenvey W
J Vasc Surg; 1988 Oct; 8(4):395-401. PubMed ID: 2459420
[TBL] [Abstract][Full Text] [Related]
25. In vivo platelet release in myeloproliferative disorders.
Ireland H; Lane DA; Wolff S; Foadi M
Thromb Haemost; 1982 Aug; 48(1):41-5. PubMed ID: 6215739
[TBL] [Abstract][Full Text] [Related]
26. Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery.
Makhoul RG; McCann RL; Austin EH; Greenberg CS; Lowe JE
Ann Thorac Surg; 1987 Jun; 43(6):617-21. PubMed ID: 3496060
[TBL] [Abstract][Full Text] [Related]
27. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
Cadroy Y; Horbett TA; Hanson SR
J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
[TBL] [Abstract][Full Text] [Related]
28. Hemodynamic and platelet response to the bolus intravenous administration of porcine heparin.
Bjoraker DG; Ketcham TR
Thromb Haemost; 1983 Feb; 49(1):1-4. PubMed ID: 6221433
[TBL] [Abstract][Full Text] [Related]
29. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation.
Olinger GN; Hussey CV; Olive JA; Malik MI
J Thorac Cardiovasc Surg; 1984 May; 87(5):673-7. PubMed ID: 6717046
[TBL] [Abstract][Full Text] [Related]
30. Platelet proteins during and after prostacyclin therapy for lower limb ischaemia--suggestion of a rebound platelet activation.
Blättler W; Furrer K; Schriber K; Kofmehl R; Massini C
Vasa; 1981; 10(3):261-3. PubMed ID: 6169225
[No Abstract] [Full Text] [Related]
31. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost.
Lessiani G; Vazzana N; Cuccurullo C; Di Michele D; Laurora G; Sgrò G; Di Ruscio P; Simeone E; Di Iorio P; Lattanzio S; Liani R; Ferrante E; Davì G
Thromb Haemost; 2011 Feb; 105(2):321-8. PubMed ID: 21103664
[TBL] [Abstract][Full Text] [Related]
32. Platelet release in coronary heart disease: effect of antiplatelet drugs and coronary artery bypass graft.
Al-Mondhiry H; Pierce WS; Pennock JL
J Lab Clin Med; 1985 Mar; 105(3):397-402. PubMed ID: 2579177
[TBL] [Abstract][Full Text] [Related]
33. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model.
Cruz CP; Eidt J; Drouilhet J; Brown AT; Wang Y; Barnes CS; Moursi MM
J Vasc Surg; 2001 Oct; 34(4):724-9. PubMed ID: 11668330
[TBL] [Abstract][Full Text] [Related]
34. Effects of iloprost, a stable prostacyclin analog, on exercise capacity and platelet aggregation in stable angina pectoris.
Bugiardini R; Galvani M; Ferrini D; Gridelli C; Mari L; Puddu P; Lenzi S
Am J Cardiol; 1986 Sep; 58(6):453-9. PubMed ID: 2428231
[TBL] [Abstract][Full Text] [Related]
35. The role of unfractionated heparin for the antiaggregatory effect of aspirin in patients undergoing carotid endarterectomy: Results of an observational clinical study.
Brenner T; Schmitt FC; Demirel S; Salgado E; Celi de la Torre JA; Göring M; Bruckner T; Böckler D; Weigand MA; Hofer S; Attigah N
Vascular; 2017 Feb; 25(1):19-27. PubMed ID: 26993144
[TBL] [Abstract][Full Text] [Related]
36. Acute thrombogenicity of arterial prostheses exposed to reduced blood flow in dogs: effects of heparin, aspirin, and prostacyclin.
Merhi Y; Bernier J; Marois Y; Guidoin R
J Cardiovasc Pharmacol; 1995 Jul; 26(1):1-5. PubMed ID: 7564348
[TBL] [Abstract][Full Text] [Related]
37. Reversal of depressed oxygen consumption accompanying in vivo protamine sulphate-heparin interactions by the prostacyclin analogue, iloprost.
Wakefield TW; Wrobleski SK; Stanley JC
Eur J Vasc Surg; 1990 Feb; 4(1):25-31. PubMed ID: 1691112
[TBL] [Abstract][Full Text] [Related]
38. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.
Darius H; Hossmann V; Schrör K
Klin Wochenschr; 1986 Jun; 64(12):545-51. PubMed ID: 2426514
[TBL] [Abstract][Full Text] [Related]
39. [Iloprost (Ilomedine) and extracorporeal circulation with conventional heparinization in a patient with heparin-induced thrombocytopenia].
Corbeau JJ; Jacob JP; Moreau X; Cottineau C; De Brux JL; Delhumeau A
Ann Fr Anesth Reanim; 1993; 12(1):55-9. PubMed ID: 7687835
[TBL] [Abstract][Full Text] [Related]
40. Stabilization of standard platelet concentrates and minimization of the platelet storage lesion by a prostacyclin analogue.
Elias M; Heethuis A; Weggemans M; Bom V; Blom N; McShine RL; Halie MR; Smit Sibinga CT
Ann Hematol; 1992 Jun; 64(6):292-8. PubMed ID: 1379080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
